Genentech
A Member of the Roche Group

2023 Independent Medical Education Request for Proposal

Issue Date: September 8, 2023

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.
Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Genentech
A Member of the Roche Group

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 8 weeks to complete a full application. Please include “SMA RFP Sept 2023” in the title your program	November 2, 2023
Step 2	After 1 week, respective Genentech Medical Education Managers will review and provide notification of final decisions via email	November 9, 2023

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available RFP Focus Area:

Focus	Opportunity
Therapeutic Area: Neurologic Rare Disease **Disease:** Spinal Muscular Atrophy **Learning Audience:** Neurologists **Support Available:** Up to $250,000	Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease characterized by progressive muscle weakness caused by degeneration of lower motor neurons in the spinal cord and brainstem. Abnormal bulbar function is a well-known complication of SMA resulting in problems with communication and deglutition due to weakness in the oropharyngeal musculature controlled by the cranial nerves in the pons and medulla. Bulbar dysfunction is not captured by standard motor function measures, and standardized, validated measures to assess bulbar function in individuals with SMA have not yet been established. Genentech is seeking to support independent medical education that addresses best practices in assessment of bulbar function in individuals with SMA and how it supports clinical management, treatment decisions and outcomes in those with SMA. **References:** 1. Dunaway Young S, Pasternak A, Duong T, McGrattan KE, Stranberg S, Maczek E, Dias C, Tang W, Parker D, Levine A, Rohan A, Wolford C, Martens W, McDermott MP, Darras BT, Day JW. Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes. J Neuromuscul Dis. 2023;10(2):199-209. doi: 10.3233/JND-221573. PMID: 36776075; PMCID: PMC10258884. 2. Dunaway Young, Sally et al. 'Development of an International SMA Bulbar Assessment for Inter-professional Administration'. 1 Jan. 2023 : 639 – 652.